Lurasidone for the treatment of schizophrenia in adult and paediatric populations

Teresa Guilera, Juan Pablo Chart Pascual, Maria del Carmen Blasco, Pilar Calvo Estopiñán, Rubén Asensio Piernas González, Isabel Ramírez Martínez, Cristóbal Rodríguez Moyano, Rita Prieto Pérez, Irene Gabarda-Inat, Juan L Prados-Ojeda, Marina Diaz-Marsà, Manuel Martín-Carrasco

Abstract

Schizophrenia is a common debilitating disorder characterized by significant impairments in how reality is perceived, combined with behavioural changes. In this review, we describe the lurasidone development programme for adult and paediatric patients. Both the pharmacokinetic and pharmacodynamic characteristics of lurasidone are revisited. In addition, pivotal clinical studies conducted on both adults and children are summarized. Several clinical cases, which demonstrate the role of lurasidone in real-world practice, are also presented. Current clinical guidelines recommend lurasidone as the first-line treatment in the acute and long-term management of schizophrenia in both adult and paediatric populations.

Article Details

Article Type

Review

DOI

10.7573/dic.2022-10-1

Categories

Publication Dates

Accepted: ; Published: .

Citation

Guilera T, Chart Pascual JP, Blasco MDC, Calvo Estopiñán P, Piernas González RA, Ramírez Martínez I, Rodríguez Moyano C, Prieto Pérez R, Gabarda-Inat I, Prados- Ojeda JL, Diaz-Marsà M, Martín-Carrasco M. Lurasidone for the treatment of schizophrenia in adult and paediatric populations. Drugs Context. 2023;12:2022-10-1. https://doi.org/10.7573/dic.2022-10-1

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.